Lack of pharmacokinetic interaction between aliskiren, a novel direct renin inhibitor, and celecoxib in healthy volunteers.

被引：0
|
作者：
Agarwal, A.
Vaidyanathan, S.
Dieterich, H. A.
Yeh, C.
Howard, D.
Dole, W. P.
机构：
[1] Novartis Pharma AG, Basel, Switzerland
[2] Novartis Pharmaceut Corp, E Hanover, NJ USA
[3] Novartis Inst Biomed Res, Cambridge, MA USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2007年 / 81卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S109 / S110
页数：2
相关论文
共 50 条
  • [1] Assessment of pharmacokinetic interaction between aliskiren, a novel direct renin inhibitor, and metformin in healthy volunteers.
    Reynolds, C.
    Vaidyanathan, S.
    Dieterich, H. A.
    Yeh, C.
    Howard, D.
    Dole, W. P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 : S110 - S110
  • [2] Assessment of the pharmacokinetic interaction between the oral direct renin inhibitor aliskiren and furosemide: A study in healthy volunteers.
    Zhao, C.
    Vaidyanathan, S.
    Dieterich, H. A.
    Yeh, C.
    Howard, D.
    Dole, W. P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 : S110 - S110
  • [3] Pharmacokinetic interaction of the oral renin inhibitor aliskiren with hydrochlorothiazide in healthy volunteers.
    Dieterich, H
    Kemp, C
    Vaidyanathan, S
    Yeh, C
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P12 - P12
  • [4] Lack of pharmacokinetic interaction between morphine and dextromethorphan in healthy volunteers.
    Caruso, FS
    Johnson, DA
    Noonan, PK
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (02) : 122 - 122
  • [5] A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects
    Ayalasomayajula, Surya
    Tchaloyan, Stephanie
    Yeh, Ching-Ming
    Bizot, Marie-Noelle
    Dieterich, Hans Armin
    Howard, Dan
    Dole, William P.
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (03) : 717 - 726
  • [6] Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers
    Vaidyanathan, S.
    Valencia, J.
    Kemp, C.
    Zhao, C.
    Yeh, C-M
    Bizot, M-N
    Denouel, J.
    Dieterich, H. A.
    Dole, W. P.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2006, 60 (11) : 1343 - 1356
  • [7] Aliskiren, an oral direct renin inhibitor, has no effect on the pharmacokinetics or pharmacodynamics of a single dose of acenocoumarol in healthy volunteers.
    Huang, H. A.
    Vaidyanathan, S.
    Yeh, C.
    Dieterich, H. A.
    Dole, W. P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S59 - S60
  • [8] Aliskiren, an orally effective renin inhibitor, shows dose linear pharmacokinetics in healthy volunteers.
    Vaidyanathan, S
    Limoges, D
    Yeh, C
    Dieterich, H
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P64 - P64
  • [9] PHARMACOKINETIC INTERACTION BETWEEN ROSUVASTATIN AND FENOFIBRATE IN HEALTHY VOLUNTEERS.
    Yi, S.
    Kim, M.
    Han, S.
    Park, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S62 - S62
  • [10] Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers
    Waldmeier, Felix
    Glaenzel, Ulrike
    Wirz, Bernard
    Oberer, Lukas
    Schmid, Dietmar
    Seiberling, Michael
    Valencia, Jessica
    Riviere, Gilles-Jacques
    End, Peter
    Vaidyanathan, Sujata
    DRUG METABOLISM AND DISPOSITION, 2007, 35 (08) : 1418 - 1428
12345